Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer

Journal of Surgical Oncology

Volumn 97, Issue 7, 2008, Pages 583-591

  Liu, Liqian ^a   Coker, Ann L ^a   Du, Xianglin L ^a   Cormier, Janice N ^b   Ford, Charles E ^a   Fang, Shenying ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Older men; Prostate cancer; Radical prostatectomy; Survival; Treatment

Indexed keywords

AGE DISTRIBUTION; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; GEOGRAPHIC DISTRIBUTION; GLEASON SCORE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; WATCHFUL WAITING;

AGED; HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 44849097287     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21028     Document Type: Article

References (48)

1. Presti J: Neoplasms of the prostate gland. In: Tanagho EA, McAninch JW, editors. Smith's general urology. 16th edition. New York: Lange Medical Books/McGraw Hill; 2004. pp 367-385.
2. Graversen PH, Nielsen KT, Gasser TC, et al.: Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990;36:493-498.
3. Potters L, Klein EA, Kattan MW, et al.: Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 2004;71:29-33.
4. Lee D: Radical prostatectomy improves cancer-specific survival but not overall survival in early-stage prostate cancer. Clin Prostate Cancer 2003;2:15-17.
5. Holmberg L, Bill-Axelson A, Helgesen F, et al.: A randomized trial comparing radical prostatectomy with watchful-waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
6. Kupelian PA, Elshaikh M, Reddy CA, et al.: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-3385.
7. Keyser D, Kupelian PA, Zippe CD, et al.: Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: Radiation therapy or surgery? Int J Radiat Oncol Biol Phys 1997;38:723-729.
8. D'Amico AV, Whittington R, Kaplan I, et al.: Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 1997;37:1053-1058.
9. D'Amico AV, Whittington R, Kaplan I, et al.: Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys 1997;39:335-340.
10. Martinez AA, Gonzalez JA, Chung AK, et al.: A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer 2000;88:425-432.
11. Byar DP, Corle DK: VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer. Veterans Administration Cooperative Urological Research Group. Urology 1981;17:7-11.
12. Paulson DF: Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. NCI Monographs 1988;7: 127-131.
13. Akakura K, Isaka S, Akimoto S, et al.: Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: Radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999;54:313-318.
14. Bill-Axelson A, Holmberg L, Ruutu M, et al.: Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful-waiting in early prostate cancer. N Engl J Med 2005; 352:1977-1984.
15. Hutchins LF, Unger JM, Crowley JJ, et al.: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
16. Trimble EL, Carter CL, Cain D, et al.: Representation of older patients in cancer treatment trials. Cancer 1994;74:2208-2214.
17. Unger JM, Hutchins LF, Albain KS: Underrepresentation of elderly patients in cancer clinical trials: Causes and remedial strategies. In: Balducci L, Lyman GH, Ershler WB, et al.: Comprehensive Geriatric Oncology. 2nd edition. New York, NY: Taylor & Francis; 2004. pp 259-274.
18. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975_2002/ (accessed August 22, 2005).
19. Potosky AL, Riley GF, Lubitz JD, et al.: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-748.
20. Warren JL, Klabunde CN, Schrag D, et al.: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:3-18.
21. Du XL, Goodwin JS: Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer 2001; 92:730-737.
22. National Cancer Institute. http://www.cancer.gov/cancertopics/ pdq/treatment/prostate/healthprofessional (accessed June 21 2006).
23. The National Comprehensive Cancer Network. Practice Guidelines in Oncology, Prostate Cancer, v.1. 2005.
24. National Cancer Institute, Bethesda, MD. The SEER program code manual. NIH Publication No. 94-1999. Revised Edition, 1994.
25. American Medical Association. Physicians' Current Procedural Terminology - CPT 2000. Chicago: American Medical Association; 2000.
26. Du XL, Freeman JL, Goodwin JS: Information on radiation treatment in patients with breast cancer: The advantages of the linked medicare and SEER data. J Clin Epidemiol 1999;52:463-470.
27. Virnig BA, Warren JL, Cooper GS, et al.: Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40: 49-54.
28. Du XL, Fang S, Coker AL, et al.: Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate cancer: Findings from a large community-based cohort. Cancer 2006;106:1276-1285.
29. Warren JL, Harlan LC, Fahey A, et al.: Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40: 55-61.
30. Du XL, Goodwin JS: Patterns of use of chemotherapy for breast cancer in older women: Findings from Medicare claims data. J Clin Oncol 2001;19:1455-1461.
31. U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th edition. Los Angeles, CA: PMIC; 1996.
32. Health Care Financing Administration. HCFA Data Dictionary: Revenue Center Codes. June 17, 1999.
33. Du XL, Chan W, Giordano S, et al.: Variation in modes of chemotherapy administration for breast cancer and association with hospitalization for chemotherapy-related toxicity. Cancer 2005;104:913-924.
34. National Cancer Institute. http://healthservices.cancer.gov/seer- medicare/program/comorbidity.html (accessed on August 22, 2005).
35. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
36. Romano PS, Roos LL, Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46:1075-1079.
37. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
38. Litwiller SE, Djavan B, Klopukh BV, et al.: Radical retropubic prostatectomy for localized carcinoma of the prostate in a large metropolitan hospital: Changing trends over a 10-year period (1984-1994). Dallas Outcomes Research Group for Urological Disorders. Urology 1995;45:813-822.
39. Kleinbaum DG: Survival analysis: A self-learning text. New York, NY; Springer-Verlag: 1996.
40. Lu-Yao GL, Yao SL: Population-based study of long-term survival in patients with clinically localised prostate cancer Lancet 1997;349:906-910.
41. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 11 Regs Public-Use Nov 2001 Sub (1992-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
42. Roehl KA, Han M, Ramos CG, et al.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004;172:910-914.
43. Pisansky TM, Kahn MJ, Rasp GM, et al.: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997;79:337-344.
44. Begg CB, Riedel ER, Bach PB, et al.: Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-1144.
45. Bach PB, Pham HH, Schrag D, et al.: Primary care physicians who treat blacks and whites. N Engl J Med 2004;351:575-584.
46. Ries LAG, Eisner MP, Kosary CL, et al.: SEER Cancer Statistics Review, 1975-2002, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975_2002/ (accessed August 22, 2005).
47. Steineck G, Helgesen F, Adolfsson J, et al.: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-796.
48. Potosky AL, Davis WW, Hoffman RM, et al.: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 2004;96: 1358-1367.